WASHINGTON, Sept. 20 /PRNewswire/ -- Jim Greenwood, president of the
Biotechnology Industry Organization (BIO), issued the following statement
on the approval by the Senate Committee on Health, Education, Labor and
Pensions of the nomination of Andrew von Eschenbach, M.D., as commissioner
of the Food and Drug Administration (FDA):
"Dr. Andrew von Eschenbach is an outstanding choice to serve as
commissioner of the FDA. He will provide strong, certain leadership to this
critical agency that protects our nation's public health.
"Dr. von Eschenbach's experience as a cancer surgeon and his leadership
as director of the National Cancer Institute afford him unique insights
into the critical need to advance new treatments for patients with
life-threatening illnesses. As a teacher and academician, he appreciates
the importance of education and research in achieving scientific
breakthroughs.
"As I said a year ago when President Bush nominated Dr. von Eschenbach,
the country needs a confirmed FDA commissioner to ensure this agency is
credible, predictable, and effective in protecting the public health.
"I urge the Senate to act on the Committee's recommendation to confirm
Dr. von Eschenbach prior to adjourning. This confirmation will be a vital
step forward in strengthening the FDA to allow it to better accomplish its
mission of getting safe and effective products into the hands of patients
and other consumers while assuring public confidence in these products."
BIO represents more than 1,100 biotechnology companies, academic
institutions, state biotechnology centers and related organizations across
the United States and 31 other nations. BIO members are involved in the
research and development of healthcare, agricultural, industrial and
environmental biotechnology products. http://www.bio.org
SOURCE Biotechnology Industry Organization
 back to top
Related links:
http://www.bio.org/
CONTACT:
Stephanie Fischer of Biotechnology Industry
Organization, +1-202-312-9263
|
